RecruitingEarly Phase 1NCT05245058

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd

Enrollment

150 participants

Start Date

Jan 21, 2022

Study Type

INTERVENTIONAL

Conditions

HER2-Positive Advanced Solid Tumors

Summary

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SPH5030 tablets for people with her2-positive advanced solid tumors. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSPH5030 tablets

SPH5030 tablets orally once or twice daily.

Locations(17)

Anhui provincial hospital

Hefei, Anhui, China

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Guangxi Cancer Hospital

Nanning, Guangxi, China

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Anyang Cancer Hospital

Anyang, Henan, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Linyi Cancer Hospital

Linyi, Shandong, China

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

The First Affiliated Hospital of Bengbu Medical University

Bengbu, China

The second people's hospital of neijiang

Neijiang, China

Tianjin Cancer Hospital Airport Hospital

Tianjin, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05245058

Related Trials

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

NCT056816501 location

Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid Tumors

ACTRN126200005929431 location